Skip to Main Content

Clinical Studies and Protocols

Site Map Investigators Log-in
(JKR-0978) A Phase 2, Open-Label, Single-Arm study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa


 Return to List of Clinical Studies
 Return to List of Protocols for Psoriasis and Skin Diseases
A Phase 2, Open-Label, Single-Arm study of the Safety of INCB054707 in Participants With Hidradenitis Suppurativa

Principal Investigator:
James G. Krueger M.D., Ph.D.

Investigators:

Contact Information:
Clinical Research Support Office
1230 York Avenue
New York, NY 10065
Telephone: 1.800.RUCARES
Email: RUCARES@Rockefeller.edu
Enrollment Status:
Open to Enrollment

Brief Summary of Protocol:
This study is being done to evaluate the safety and tolerability of INCB054707 in subjects with moderate to severe hidradenitis suppurativa (HS). HS is a rare, long-term skin condition that causes you to get painful bumps under your skin in the hair roots near some of your sweat glands. This study will also evaluate the efficacy of INCB054707, the effect of INCB054707 on proteins present in the skin and the blood, the level of INCB054707 in the blood, and the effect of INCB054707 on quality of life.



Detailed Description of Protocol:
This study is being done to evaluate the safety and tolerability of INCB054707 in subjects with moderate to severe hidradenitis suppurativa (HS). HS is a rare, long-term skin condition that causes you to get painful bumps under your skin in the hair roots near some of your sweat glands. This study will also evaluate the efficacy of INCB054707, the effect of INCB054707 on proteins present in the skin and the blood, the level of INCB054707 in the blood, and the effect of INCB054707 on quality of life.
INCB054707 tablet is an experimental drug which means it is not yet approved by the United States (US) Food and Drug Administration. It is not approved for use outside of studies like this one.
INCB054707 is in a class of medications called Janus family of tyrosine kinase inhibitors. It works by blocking an over-active protein which in turn suppresses activity of your immune system cells that lead to inflammation on your skin. Since HS is a chronic inflammatory skin disease, it is believed that INCB054707 could help in the treatment of this condition.




What specifically makes a person eligible for the study?
You may be eligible to enter this study:

- If you are between the ages of 18 and 75
- If you have been diagnosed with hidradenitis suppurativa


Gender:
Both

Age(s):
18-75

Children permitted to participate:
No

Potential Benefits.....




Compensation:
Compensation is provided.